Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Items 301–400 of 565
Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS
Nehar-Belaid, D., Sokolowski, M. J., Ravichandran, S., Banchereau, J., Chaussabel, D., & Ucar, D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101842 · Cited by 20
Carter, C. S., Khamiss, D., Matheny, M. E., Toklu, H. Z., Kirichenko, N., Strehler, K. Y. E., Tümer, N., Scarpace, P. J., & Morgan, D. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu238 · Cited by 20
“Furthermore, mTOR is central to the regulation of cellular activities such as growth and survival, nutrient sensing, protein synthesis, and autophagy (30).”
BackgroundA Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis
Sharlow, E. R., Leimgruber, S., Lira, A. K., McConnell, M. J., Norambuena, A., Bloom, G. S., Epperly, M. W., Greenberger, J. S., & Lazo, J. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00909 · Cited by 20
Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?
Cazzola, M., Matera, M. G., Rogliani, P., & Calzetta, L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492548 · Cited by 20
“Similar problems are likely to emerge for rapalogs and mTOR kinase inhibitors [54].”
BackgroundPharmacological Approaches to Decelerate Aging: A Promising Path
Hassani, B., Goshtasbi, G., Nooraddini, S., & Firouzabadi, N. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4201533 · Cited by 20
“In general, inhibition of the mTOR pathway, either genetically or pharmacologically, has shown to increase lifespan in different species [137].”
Shintani, T., Shintani, H., Sato, M., & Ashida, H. (2023) · GeroScience · doi:10.1007/s11357-023-00851-0 · Cited by 21
“Rapamycin substantially regulates protein homeostasis, cell proliferation, and inflammation [109].”
BackgroundHong, Y., Wang, Y., Shu, W., Li, J., Mi, Y., Chen, H., & Chen, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102835 · Cited by 20
Management of immunosuppressant agents following liver transplantation: Less is more
Ascha, M. S. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i3.148 · Cited by 19
Shibutani, S., Okazaki, H., & Iwata, H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776443 · Cited by 19
“Aging is delayed by dietary restriction in many animal species (40), and mTORC1 suppression appears to be a critical factor to explain that phenomenon (39).”
BackgroundSquillaro, T., Alessio, N., Capasso, S., Bernardo, G. D., Melone, M. A. B., Peluso, G., & Galderisi, U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102508 · Cited by 20
Compression of morbidity by interventions that steepen the survival curve
Yang, Y., Mayo, A., Levy, T., Raz, N., Shenhar, B., Jarosz, D. F., & Alon, U. (2025) · Nature Communications · doi:10.1038/s41467-025-57807-5 · Cited by 18
The hot issue: TOR signalling network in plants
Zhao, Y., & Wang, X. (2020) · Functional Plant Biology · doi:10.1071/fp20071 · Cited by 19
Dikicioǧlu, D., Eke, E. D., Eraslan, S., Oliver, S. G., & Kırdar, B. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0298-y · Cited by 18
The immunometabolic roots of aging
Ginefra, P., Hope, H. C., Lorusso, G., D’Amelio, P., & Vannini, N. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102498 · Cited by 18
Ross, J. M., Olson, L., & Coppotelli, G. (2024) · Biomolecules · doi:10.3390/biom14020162 · Cited by 18
“…together with the discoveries of genetic mutations that may affect lifespan, has changed the perspective, such that aging can now be seen as the integrated result of genetic and environmental factors, both of which could possibly be targeted to slow down and/or ameliorate the overall process [4–6].”
BackgroundPharmaceutical Intervention of Aging
Qian, M., & Liu, B. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_15 · Cited by 19
Dynamic modeling of signal transduction by mTOR complexes in cancer
Dorvash, M., Farahmandnia, M., Mosaddeghi, P., Farahmandnejad, M., Saber, H., Khorraminejad‐Shirazi, M., Azadi, A., & Tavassoly, I. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.109992 · Cited by 20
Dai, D., Liu, Y., Basisty, N., Karunadharma, P. P., Dastidar, S. G., Chiao, Y. A., Chen, T., Beyer, R. P., Chin, M. T., MacCoss, M. J., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00119-6 · Cited by 17
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans
Hagan, M. J., Shenkar, R., Srinath, A., Romanos, S. G., Stadnik, A., Kahn, M. L., Marchuk, D. A., Girard, R., & Awad, I. A. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00006 · Cited by 18
Rapamycin as a potential treatment for succinate dehydrogenase deficiency
Fan, F., Sam, R., Ryan, E., Alvarado, K., & Villa-Cuesta, E. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e01217 · Cited by 17
“Following studies demonstrating rapamycin’s potential to affect tumor growth, metabolic disorders such as diabetes, and neurodegenerative disorders, interest in rapamycin and its analogues has skyrocketed [23, 25, 26, 27].”
BackgroundInfluentialWijesinha, M. A., Hirshon, J. M., Terrin, M. L., Magder, L. S., Brown, C. H., Stafford, K. A., & Iacono, A. T. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.10297 · Cited by 18
Rapalogs Potential as Practical Alternatives to Rapamycin
Abdel‐Magid, A. F. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00215 · Cited by 17
Longitudinal Functional Study of Murine Aging: A Resource for Future Study Designs
Evans, D. S., O’Leary, M. N., Murphy, R. A., Schmidt, M., Koenig, K. L., Presley, M. P., Garrett, B., Kim, H., Li, H., Academia, E. C., et al. (2021) · JBMR Plus · doi:10.1002/jbm4.10466 · Cited by 16
“Such approaches often increase lifespan and attenuate progressive physiological decline.((3,5,37,43-47)) Despite substantive breakthroughs in geroscience, it is unclear if lifespan extension is always associated with an increase in healthy life (healthspan).”
BackgroundA patent review of mTOR inhibitors for cancer therapy (2011–2020)
Qiu, H., Wang, P., & Zhang, M. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1940137 · Cited by 16
Jamal, M., Nunes, A. C. F., Vaziri, N. D., Ramchandran, R., Bacallao, R. L., Nauli, A. M., & Nauli, S. M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114056 · Cited by 16
“Rapamycin also has a role in extending the lifespan and preventing the onset of many age-related diseases [73,74].”
BackgroundMillson, S. H., & Piper, P. W. (2014) · Oncotarget · doi:10.18632/oncotarget.2077 · Cited by 15
“Attention is therefore now being directed to the development of inhibitors that will selectively target the catalytic site of mTOR, drugs that will inhibit both TORC1 and TORC2 [24, 25] (identifier: www.”
BackgroundInfluentialCurrent progress in the therapeutic options for mitochondrial disorders.
Koňaříková, E., Markovic, A., Korandová, Z., Houštěk, J., & Mráček, T. (2020) · Physiological Research · doi:10.33549/physiolres.934529 · Cited by 16
“Further trials might benefit from other molecules targeting mTOR pathway, but with different mechanisms of action than rapamycin (Lamming et al., 2013).”
BackgroundDoes transcription-associated DNA damage limit lifespan?
Callegari, A. J. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.03.001 · Cited by 17
Vogel, K. R., Ainslie, G. R., Jansen, E. E. W., Salomons, G. S., & Gibson, K. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.10.009 · Cited by 16
“We chose to utilize Torin 1 in lieu of rapamycin because Torin 1 is highly potent and selective, and several mTORC1 (mechanistic target of rapamycin complex 1) functions are resistant to inhibition by rapamycin, yet effectively blocked by the newer analog Torin 1 [44, 45].”
MethodMetabolic Effects of Caloric Restriction
Lamming, D. W., & Anderson, R. M. (2014) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0021316.pub2 · Cited by 15
“Conversely, treatment with rapamycin significantly decreases glucose tolerance due to decreased hepatic insulin sensitivity in C57BL/6 and HET3 mice strains, rats, and in humans (Lamming et al. , 2012, 2013; Johnston et al. , 2008).”
BackgroundSelf-citationHoussaini, A., & Adnot, S. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0245ed · Cited by 15
“also involved in cellular senescence (13).”
Insights into the therapeutic strategies for aging and aging-associated diseases
Dong, R., Wu, Q., Kan, J., Fu, C., Sorrentino, V., Chow, A., Lei, Y., Wu, D., Xu, Z., Du, J., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02662-z · Cited by 16
“140 Inhibition of mTORC2 has been proven to shorten the lifespan in C. elegans 141 and in liver-speci fi c mTORC2 knockout mice.”
Fan, X., Yu, L., Xie, Y., Yan, X., Fan, W., Ishii, Y., Yu, B., & Li, R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139216 · Cited by 15
Zaini, M. A., Müller, C., Ackermann, T., Reinshagen, J., Kortman, G., Pleß, O., & Calkhoven, C. F. (2017) · Scientific Reports · doi:10.1038/srep42603 · Cited by 15
Montano, M. A., Bhasin, S., D’Aquila, R. T., Erlandson, K. M., Evans, W. J., Funderburg, N., Justice, A. C., Ndhlovu, L. C., Ojikutu, B. O., Pahor, M., et al. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0130 · Cited by 14
Cellular Senescence and Frailty in Transplantation
Lorenz, E. C., Hickson, L. J., Khairallah, P., Najafi, B., & Kennedy, C. C. (2023) · Current Transplantation Reports · doi:10.1007/s40472-023-00393-6 · Cited by 14
Proteomics and metabolomics in cancer drug development
D’Alessandro, A., & Zolla, L. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.840440 · Cited by 15
Zheng, Y., Gao, N., Fu, Y., Zhang, B., Li, X.-L., Gupta, P. K., Wong, A. J., Li, T.-F., & Han, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.151 · Cited by 14
Recent studies on anti-aging compounds with Saccharomyces cerevisiae as a model organism
Yalcin, G., & Lee, C. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.10.001 · Cited by 15
Translation of Cellular Senescence to Novel Therapeutics: Insights From Alternative Tools and Models
Inci, N., Kamali, D., Akyildiz, E. O., Tahir Turanli, E., & Bozaykut, P. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.828058 · Cited by 13
Gerasymchuk, M., Robinson, G. I., Kovalchuk, O., & Kovalchuk, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158804 · Cited by 13
“(2017) also noted that metformin and, to a lesser extent, resveratrol improved the healing process through stimulation of the AMPK pathway, which has been documented to inhibit wound healing [80], probably because of its immunosuppressive capability upon systemic administration [50,76,80].”
BackgroundCharacterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans
Zhang, A., Meecham-Garcia, G., Hong, C. N., Xie, P., Kern, C. C., Zhang, B., Chapman, H., & Gems, D. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae196 · Cited by 18
Metformin as a cellular protector; a synoptic view of modern evidences.
Wiernsperger, N. F. (2015) · PubMed Central · Cited by 13
The role of RNA helicases in aging and lifespan regulation
Park, S., Park, H. H., Son, H. G., & Lee, S. (2017) · Translational Medicine of Aging · doi:10.1016/j.tma.2017.08.001 · Cited by 12
Li, Y., & Cui, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.100 · Cited by 12
S-Adenosylmethionine Metabolism and Aging
Loenen, W. A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811060-7.00003-6 · Cited by 15
Targeting Mitochondrial Defects to Increase Longevity in Animal Models of Neurodegenerative Diseases
Casajús-Pelegay, E., Puzzo, F., Yılmazer, A., & Cagin, U. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12668-1_5 · Cited by 12
Lipid profiling of C. elegans strains administered pro-longevity drugs and drug combinations
Admasu, T. D., Batchu, K. C., Ng, L. F., Cazenave‐Gassiot, A., Wenk, M. R., & Gruber, J. (2018) · Scientific Data · doi:10.1038/sdata.2018.231 · Cited by 13
Zhu, Z., Jiang, X., Wang, F., Zhao, L., & Song, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1675194 · Cited by 11
“In IH cells, aberrant activation of this pathway upregulates HIF-1 a and VEGF, increasing cellular tolerance to stress (96, 97).”
Emerging Interventions for Elderly Patients—The Promise of Regenerative Medicine
Miller, R. R., & Roubenoff, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1272 · Cited by 12
“In humans, rapamycin is the US Food and Drug Administration (FDA) approved for use as an immunosuppressant after transplant surgery, as a treatment for renal cell cancer, and for several other highly specialized indications.(58) Rapamycin is associated with numerous adverse effects that limit its use to conditions in…”
BackgroundMendoza-Viveros, L., Marmolejo‐Gutierrez, C., Cid‐Castro, C., Escalante‐Covarrubias, Q., Montellier, E., Carreño‐Vázquez, E., Noriega, L. G., Velázquez‐Villegas, L. A., Tovar, A. R., Sassone‐Corsi, P., et al. (2023) · Glia · doi:10.1002/glia.24360 · Cited by 11
“In fact, mTOR inhibitors and autophagy inducers (Saraswat & Rizvi, 2017) are currently investigated as geroprotective agents (Cuervo, 2008; Lamming et al., 2013).”
BackgroundChemical tools for modulating autophagy
Triola, G. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.10.057 · Cited by 13
Rapamycin reduces Drosophila longevity under low nutrition
Villa-Cuesta, E., Fan, F., & Rand, D. M. (2014) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-0408043051 · Cited by 11
“References [1].”
Xiong, Z., Zang, Y., Zhong, S., Zou, L., Wu, Y., Liu, S., Fang, Z., Shen, Z., Ding, Q., & Chen, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15620 · Cited by 11
A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin
Geagea, A. G., Rizzo, M., Jurjus, A. R., Cappello, F., Leone, A., Tomasello, G., Gracia, C., Kattar, S. A., Massaad-Massade, L., & Eid, A. A. (2019) · Oncotarget · doi:10.18632/oncotarget.26641 · Cited by 16
“On the other hand, rapamycin, originally used as an antifungal agent [33], it was later approved as a potential anticancer drug [34], a specific inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway, master regulator of cell growth and metabolism implicated in a number of diseases including diabetes…”
BackgroundChronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?
Sharp, Z. D., Curiel, T. J., & Livi, C. B. (2013) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000343625 · Cited by 11
The Discovery of Druggable Anti-aging Agents
Yalcin, G., & Lee, C. (2020) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.20.0092 · Cited by 12
Lewis, C. J., & de Grey, A. D. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2330425 · Cited by 10
“It functions as a mTORC1 inhibitor, influencing a key nutrient sensing pathway, lowering protein synthesis rates and boosting autophagy [19–22], though it also acts as an immunosuppressant, which is the basis for its clinical use in preventing transplant organ rejection [23].”
Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells
Watanabe, R., Miyata, M., & Oneyama, C. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.012 · Cited by 10
Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro
Glover, T. E., Kew, V. G., & Reeves, M. B. (2014) · Journal of General Virology · doi:10.1099/vir.0.066332-0 · Cited by 9
“…active against the mTOR complex 1 (mTORC1) arm (Heitman et al., 1991; Sabatini et al., 1994). mTOR is a serine/threonine kinase controlling a range of cellular functions, including cell growth, proliferation and survival and affecting transcription and protein synthesis (Lamming et al., 2013).”
Metabolomics of Multimorbidity: Could It Be the Quo Vadis?
Dash, P., Mohapatra, S. R., & Pati, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.848971 · Cited by 9
“In the same study, a higher degree of interaction was observed among cardiometabolic and respiratory diseases including lung cancer, COPD, cerebral stroke, T2D, chronic heart disease, heart failure, and renal and liver diseases across different groups of metabolites (Lamming et al., 2013).”
BackgroundSpecies Difference in Glucuronidation Formation Kinetics with a Selective mTOR Inhibitor
Berry, L., Liu, J., Colletti, A. E., Krolikowski, P. H., Zhao, Z., & Teffera, Y. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054809 · Cited by 9
“Indeed, inhibition of mTOR by rapamycin had been found to extend life span in a number of species, including mammals, with biological effects similar, but not necessarily identical, to those found following calorie/nutrient restriction (Lamming et al., 2013; Johnson et al., 2013; Fok et al., 2013).”
BackgroundEissenberg, J. C. (2018) · Europe PMC (PubMed Central) · Cited by 9
Centonze, G., Centonze, S., Ponzone, L., & Calautti, E. (2022) · Cells · doi:10.3390/cells11071130 · Cited by 10
“Over the past several years, there has been accumulating evidence demonstrating that mTOR inhibition via rapamycin (or rapalogs), extends lifespan in yeast, worms, flies, and mice, indicating that attenuation of mTOR signaling promotes longevity in a wide range of species [82].”
BackgroundAre invertebrates relevant models in ageing research? Focus on the effects of rapamycin on TOR
Erdogan, C. S., Hansen, B. W., & Vang, O. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.12.004 · Cited by 9
mTORC1 inhibition may improve T lymphocytes affected by aging
Asghari, F., Karimi, M. H., & Pourfathollah, A. A. (2023) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2023.2232101 · Cited by 8
“Because of worse complications of mTORC2 inhibition, there is a need for specific inhibition of the mTORC1 complex in aging management [31].”
BackgroundDiscovery of deoxyandrographolide and its novel effect on vascular senescence by targeting HDAC1
Lin, Z., He, H., Xian, Y., Cai, J., Ge, Q., Guo, M., Zheng, Q., Liu, X., Mo, C., Zhang, X., et al. (2023) · MedComm · doi:10.1002/mco2.338 · Cited by 8
Peripheral tissular analysis of rapamycin’s effect as a neuroprotective agent in vivo
González-Alcocer, A., Gopar‐Cuevas, Y., Soto‐Domínguez, A., Loera‐Arias, M. D. J., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., Rodríguez‐Rocha, H., & García‐García, A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02276-6 · Cited by 8
“However, its antiaging and prophylactic usage for neurodegeneration is still debated (Lamming et al. 2013; Lamming 2016) because of diverse side effects, including dyslipidemia, glucose intolerance, insulin resistance, new-onset diabetes, and gastrointestinal disorders (Johnston et al.”
BackgroundZhang, P., Jiang, Y., Ye, X., Zhang, C., & Tang, Y. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11922 · Cited by 8
The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415
Zhang, W., Chen, B., Zhang, Y., Li, K., Hao, K., Jiang, L., Wang, Y., Mou, X., Xu, X., & Wang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.156 · Cited by 8
The mTOR Signaling Pathway in Neurodegenerative Diseases
Francois, A., Vérité, J., Bilan, A. R., Janet, T., Calon, F., Fauconneau, B., Paccalin, M., & Page, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00011-6 · Cited by 9
Hu, M. S., Li, T., Bo, Z., & Xiang, F. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219840987 · Cited by 10
Exploring the role of mTOR pathway in aging and age-related disorders
Raghuvanshi, K., Raghuvanshi, D., Kumar, D., Nepovimová, E., Valko, M., Kuča, K., & Verma, R. (2025) · EXCLI journal · doi:10.17179/excli2025-8384 · Cited by 10
“Furthermore, prolonged Akt activation has frequently been linked to cardiac dysfunction (Jia et al., 2014, Xu et al., 2013), as well as prolonged mTOR1 inhibition may increase PI3K and Akt signaling (Lamming et al., 2013).”
Myc mouse and anti-ageing therapy
Alic, N., & Partridge, L. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.02.005 · Cited by 7
The impact of cannabis use on ageing and longevity: a systematic review of research insights
Nain, S., Singh, N., Schlag, A. K., & Barnes, M. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00267-x · Cited by 7
“Although studies indicate its potential in slowing aging, further research is necessary to ascertain its efficacy (Blagosklonny 2023; Lamming et al. 2013; Lee et al. 2024; Selvarani et al. 2021).”
Zarroug, S. H. O. (2024) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2414189 · Cited by 7
Metabolic Biomarkers in Aging and Anti-Aging Research
Guest, P. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-25650-0_13 · Cited by 7
The therapeutic value of XL388 in human glioma cells
Zhong, S., Xue, J., Cao, J., Sun, B., Sun, Q., Bian, L., Hu, L., & Pan, S. (2020) · Aging · doi:10.18632/aging.103791 · Cited by 7
“com 22553 AGING mTORC1 and mTORC2, which were reflected by phosphorylated (p-) S6K1 and p-Akt Ser-473, respectively (Figure 3A) [11, 25, 26].”
BackgroundGSK3β-dependent lysosome biogenesis: An effective pathway to mitigate renal fibrosis with LM49
Ren, J., Wei, H., Sun, J., Feng, X., Zhang, Y., Yuan, H., Miao, J., Qi, X., Qiao, Y., Xiao, B., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925489 · Cited by 7
“mTORC1 in other cellular biosynthetic pathways (Lamming et al., 2013).”
Sun, R., Zhang, Y., Ma, S., Qi, H.-T., Wang, M., Duan, J.-H., Ma, S., Zhu, X., Li, G., & Wang, H. (2015) · Microbiology and Immunology · doi:10.1111/1348-0421.12321 · Cited by 7
New anti-aging strategies: a narrative review
Stojić, V., Štrbac, T., & Stanimirović, A. (2023) · Acta Dermatovenerologica Alpina Pannonica et Adriatica · doi:10.15570/actaapa.2023.29 · Cited by 9
Advances in pharmacological interventions of aging in mice
Qian, M., & Liu, B. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.11.002 · Cited by 6
Targeting Alternative Splicing for Reversal of Cellular Senescence in the Context of Aesthetic Aging
Bramwell, L. R., & Harries, L. W. (2020) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000007618 · Cited by 6
Shosaku, J. (2017) · Immunology · doi:10.1111/imm.12840 · Cited by 6
Sills, E. S., Harrity, C., Wood, S. H., & Tan, S. L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071147 · Cited by 5
“Rapamycin at relatively low dose is more likely to confer a beneficial response with preferential mTORC1 inhibition, while blunting any undesirable effects on mTORC2 [63].”
BackgroundWei, D., Zhang, H., Xu, W., Zhang, B., Zhang, L., Lan, L., Li, Y., Shi, Y., & Song, X. (2025) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2025.113200 · Cited by 6
Wang, L., Shao, Q., Wu, H., & Cheng, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1618984 · Cited by 5
What is the clinical evidence to support off-label rapamycin therapy in healthy adults?
Hands, J. M., Lustgarten, M. S., Frame, L. A., & Rosen, B. S. (2025) · Aging · doi:10.18632/aging.206300 · Cited by 7
“Rapamycin’s ability to delay age -related disease has been replicated, most notably in the intervention testing program (ITP), where consistent extensions for median and maximum lifespan in both male and female mice have been identified [22].”
Realistic expectations for changes to average human lifespan in the near future
Johnson, A. A. (2025) · Biogerontology · doi:10.1007/s10522-025-10318-8 · Cited by 5
“Adverse side effects for rapamycin have also been reported in mice (Wilkinson et al. 2012) and humans (Lee et al. 2024), though this may be resolved by utilizing rapalogs (Lamming et al. 2013) or a lower, intermittent dose of rapamycin (Hudson et al. 2024).”
Mechanisms of aging in the cardiovascular system: challenges and opportunities
Zhao, X., Yang, X., Lin, Y., Lei, R., Ding, W., He, X.-Y., Cao, Y. J., Zhang, D., Liu, P., Liang, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635736 · Cited by 5
“Rapamycin and its analogues (rapalogs), on the other hand, reduce SASP expression levels by inhibiting mTOR activity and can prolong the healthy lifespan and overall lifespan of mice (221, 222).”
Timing of TORC1 inhibition dictates Pol III involvement in Caenorhabditis elegans longevity
Malik, Y., Silva, I. G., Diazgranados, R. R., Selman, C., Alic, N., & Tullet, J. M. A. (2024) · Life Science Alliance · doi:10.26508/lsa.202402735 · Cited by 6
Gorczynski, R. M., Alexander, C., Brandenburg, K., Chen, Z., Heini, A. F., Neumann, D., Mach, J. P., Rietschel, E., Tersikh, A., Ulmer, A. J., et al. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.06.003 · Cited by 5
“Rapamycin (Wyeth Chemicals) was injected ip at 48 h intervals as indicated at a dose of 1 mg/Kg/mouse [20,21].”
MethodWu, P., & Choudhary, A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch3 · Cited by 5
Impact of aging at cellular and organ level
Chimata, A. V., Deshpande, P., Singh, A. P., & Singh, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90235-9.00009-4 · Cited by 6
Vershinina, Y. S., Krasnov, G. S., Garbuz, D. G., Shaposhnikov, M. V., Fedorova, M., Pudova, E. A., Katunina, I. V., Kornev, A. B., Zemskaya, N. V., Kudryavtsev, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109095 · Cited by 5
“…hand, there is incontrovertible evidence that reducing TORC1 activity—for example, through caloric restriction [10] or administration of rapamycin with food—increases longevity in model organisms, including S. cerevisiae , C. elegans , D. melanogaster , M. musculus , and other species [11,12].”
BackgroundDirect modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressants
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Racskó, M., Kelemen, B., Herczeg, M., Nagy, T. M., Kövér, K. E., Mitra, A., et al. (2025) · eLife · doi:10.7554/elife.97341.3 · Cited by 5
Raynes, Y., Santiago, J., Lemieux, F. A., Darwin, L. J., & Rand, D. M. (2024) · BMC Genomics · doi:10.1186/s12864-024-10647-x · Cited by 5
“Yet, rapam-ycin therapy in humans has been hindered by the adverse side effects of prolonged use, including immunosuppression, hyperlipidemia, and hyperglycemia [19, 23].”
BackgroundGlucose Metabolism, Insulin, and Aging
Boemi, M., Furlan, G., & Luconi, M. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801816-3.00029-7 · Cited by 8
Grootaert, M. O. J., Kurdi, A., Munck, D. G. D., Martinet, W., & Meyer, G. R. Y. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-805421-5.00013-6 · Cited by 6
In silico clinical trials for anti-aging therapies
Menéndez, J. A., Cuyàs, E., Folguera-Blasco, N., Verdura, S., Martín-Castillo, B., Joven, J., & Alarcón, T. (2019) · Aging · doi:10.18632/aging.102180 · Cited by 5
“, metformin and rapamycin) [10,11], the design of bona fide anti-aging clinical trials with the existing (and with a yet-to-be funded) pipeline of healthspan/resilience-/lifespan-promoting treatments will pose a unique set of challenges, namely: a.”
Background
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.